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Background. Cyclin D1 regulates the G1 to S transition of cell cycle. Its deregulation or overexpression may lead to disturbance in
the normal cell cycle control and tumour formation. Overexpression of cyclin D1 has been reported in various tumors of diverse
histogenesis. This case control retrospective study was carried out to study the immunohistochemical reactivity and expression of
cyclin D1 and its association with site, clinical staging, and histopathological diﬀerentiation of oral squamous cell carcinoma
(OSCC). Methods. Forty formalin-ﬁxed paraﬃn-embedded tissue blocks of biopsy specimens of oral squamous cell carcinoma
were immunohistochemically evaluated for expression of cyclin D1. Results. Cyclin D1 expression was seen in 45% cases of OSCC.
It did not correlate with site and clinical staging. Highest expression was seen in well-diﬀerentiated, followed by moderately dif-
ferentiated, and poorly diﬀerentiated squamous cell carcinomas, with a statistically signiﬁcant correlation. Conclusion.C y c l i nD 1
expression signiﬁcantly increases with increase in diﬀerentiation.
1.Introduction
The multistage process of carcinogenesis involves the pro-
gressive acquisition of mutations and epigenetic abnormal-
ities in the expression of multiple genes, with an important
group among them being those involved in cell cycle control
[1].
The orderly progression of the cells through the various
phases of cell cycle, namely, G1, S, G2, and M phases is pre-
cisely governed by a series of proteins called “cyclins,” which
exert their eﬀect by binding and activating the cyclin-depen-
dent kinases (CDK) [2].
Cyclin D1, a 45kD (kilo Dalton) protein encoded by
cyclinD1 gene (CCND1) located on chromosome 11q13, is a
partofthemolecularsystemthatregulatesthecellcycleG1to
S transition [2]. It was ﬁrst isolated as Parathyroid adeno-
matosis 1 gene (PRAD1) oncogene clonally rearranged and
overexpressed in parathyroid adenomas and is identical to
B-cell lymphoma1 gene (bcl-1) protoncogene, which is tran-
slocated and overexpressed in a subset of B-cell neoplasms
[1].
Overexpression of cyclin D1 leads to shortening of G1
phase and less dependency on growth factors resulting in ab-
normal cell proliferation which in turn might favour the
occurrence of additional genetic lesions [1].
Cyclin D1 expression has been studied in various carci-
nomas including oral squamous cell carcinomas. Some stud-
ies have been carried out to correlate the expression of cyclin
D1 with histological grading of this neoplasm [2–5]. How-
ever, the results have not been consistent and conclusive.
Hence, this retrospective laboratory-based study was un-
dertaken to study the expression of cyclin D1 in oral squa-
mous cell carcinoma and to correlate its expression with his-
tological diﬀerentiation.2 The Scientiﬁc World Journal
2. MaterialsandMethods
Forty formalin-ﬁxed paraﬃn-embedded (FFPE) tissue
blocks of incisional biopsy specimens, which were histolo-
gically diagnosed as oral squamous cell carcinoma (OSCC),
were retrieved from the archives of Department of Oral and
Maxillofacial Pathology of the Paciﬁc Dental College, Udai-
pur, India. One FFPE tissue block ofnormal oral mucosawas
included as a positive control and one squamous cell carci-
noma tissue with exclusion of primary antibody was used as
negative control.
From each FFPE tissue block, 3-4μ thick sections were
cut and stained by H&E stain for histopathological grading.
Tumours were graded according to Broder’s criteria [6]i n t o
well- (WDSCC; n = 13), moderately (MDSCC; n = 16), and
poorly diﬀerentiated (PDSCC; n = 11) ones.
Immunohistochemical study was carried out using poly-
mer-labelling technique (Dako, Envision). Sections were de-
waxed, washed in alcohol and antigen retrieval was carried
out in a Decloaking Chamber (Pascal) with 10mM Citra
solutionat125◦Cfor30secondsfollowedby90◦Cf o r1 0s e c -
onds. Slides were cooled naturally and brought to room tem-
perature.SlideswereplacedinsidetheDakoAutostainerUni-
versal Staining System, an automated immunohistochem-
istry staining system. Endogenous peroxidase was block-
ed by using 0.3% hydrogen peroxide in methanol at room
temperature for 10 minutes. Slides were washed with
phosphate-buﬀered saline (PBS) brieﬂy and incubated with
primary antibody (Cyclin D1) for 60 minutes. Section were
again washed with PBS, incubated with the polymer for
30 minutes, and washed again with PBS. Diaminobenzidine
(DAB) was used as the chromogen in hydrogen peroxide
for 10 minutes. Sections were then counterstained with
haemotoxylin,mounted,andstudiedunderlightmicroscope
for immunorecativity.
Presence of brown-coloured end product at the site of
target antigen was indicative of positive immunoreactivity.
The negative control demonstrated the absence of staining.
Tissue section of positive control showed brown staining of
the cells of basal and parabasal layers and was conﬁrmed as
being positively stained (Figure 1). The evaluation of study
cases was done subsequently in a similar way for IHC reac-
tivity. Only the slides showing positive reactivity were furth-
er evaluated for cyclin D1 expression as per criteria described
by Gu et al. [7].
In every slide ten, hot spot areas were selected and obser-
ved under higher (400X) magniﬁcation with a grid. Percent-
age of IHC positive tumour cells per hot spot was calculated
and the mean percentage per slide (labelling index) was
determined (Figure 2). A labelling index score of 1, 2, 3, or 4
was assigned for labelling indices 1–25%, 26–50%, 51–75%,
and >75%, respectively.
The intensity of cyclin D1 immunostaining (Figure 3)
was evaluated on the basis of microscopic appearance as
weak, intermediate, or strong and an intensity score of 1, 2,
or 3 was assigned to them, respectively.
A ﬁnal expression score was calculated by multiplying
labelling index score with intensity score, based on which
the cyclin D1 expression was determined as weak (score 1–
4), moderate (score 5–8), or strong (score 9–12).
Figure 1:PhotomicrographdepictingCyclinD1expressioninbasal
and suprabasal layers of normal epithelium.
Figure 2: Photomicrograph depicting labelling index calculation
under high magniﬁcation with a grid.
Figure 3: Photomicrograph depicting intensity evaluation under
high magniﬁcation.
All the relevant clinical, histopatholocal, and immuno-
histochemical data so obtained were tabulated and subjected
to appropriate statistical analysis using the SPSS 11 statistical
software.
3. Results
Cyclin D1 positivity was seen in 18 cases (45%) of OSCC.
Further distribution of cyclin D1 reactivity in accordance
with site, clinical stage, and histopathological diﬀerentiation
are explained in Table 1. The labelling index scores, intensityThe Scientiﬁc World Journal 3
Table 1: Distribution of site, clinical staging, histopathological diﬀerentiation of OSCC, and their IHC reactivity.
Distribution category Total number
IHC reactivity
Positive
(n)
Negative
(n)
% of positive
reactivity P
Site
0.282
NS
Alveolus 11 07 04 63.63
Buccal mucosa 13 05 08 38.46
Tongue 15 05 10 33.33
Lip 01 01 00 100
Clinical staging
0.867
NS
Stage I 06 03 03 50
Stage II 07 04 03 57.14
Stage III 13 05 08 38.4
Stage IV 14 06 08 42.8
Histopathological
diﬀerentiation
WDSCC 13 09 04 69.23
0.011 S MDSCC 16 08 08 50
PDSCC 11 01 10 9.09
OSCC (total) 40 18 22 45
Table 2: Labelling index score, and intensity in relation to histopathological diﬀerentiation.
OSCC diﬀerentiation
Intensity Labelling index score
Weak (n) Intermediate (n)S t r o n g ( n) P Score 1 Score 2 Score 3 Score 4 P
WDSCC 4 3 2 0.075 1 5 3 0 0.361
MDSCC 2 4 2 (NS) 1160 (NS)
P D S C C 0 0 1 0001
OSCC 6 7 5 2 6 9 1
Table 3: Cyclin D1 expression in relation to site, clinical staging, and histopathological distribution.
Distribution category
Cyclin D1 expression
Weak (n) Moderate
(n) Strong (n) P
Site
0.255 NS
Alveolus 04 01 02
Buccal mucosa 01 02 02
Tongue 04 00 01
Lip 00 01 00
Clinical Staging
0.866 NS
Stage I 01 01 01
S t a g e I I 0 30 10 0
Stage III 02 01 02
S t a g e I V 0 30 10 2
Histopathological
diﬀerentiation
W D S C C 0 70 00 2
0.042 S M D S C C 0 20 40 2
P D S C C 0 00 00 1
OSCC (total) 09 04 054 The Scientiﬁc World Journal
of staining, expressions graded, and their correlations with
clinical and histological parameters are elaborated in Tables
2 and 3.
Both cyclin D1 reactivity and expression did not show
any correlation with site and clinical staging of the OSCC
(Tables 1 and 3). The histopathological diﬀerentiation show-
ed a positive correlation with increase in both the reacti-
vity and expression with increasing diﬀerentiation (Tables 1
and 3). The labelling index score and intensity did not cor-
relate with OSCC diﬀerentiation (Table 2).
4. Discussion
The present study was carried out to study the immuno-
histochemical reactivity and expression of cyclin D1 and its
association with site, clinical staging, and histopathological
diﬀerentiation of oral squamous cell carcinoma.
T h eI H Cr e a c t i v i t yf o rc y c l i nD 1w a se v a l u a t e do nt h e
basis of presence or absence of brown staining. Nuclear and
cytoplasmic stainings in all the cases of positivity were ob-
served, which was similar to other studies [3, 4, 7–19]. How-
e v e r ,G i l l e t te ta l .[ 20] considered only cytoplasmic staining
as negative, and Vora et al. [5] reported exclusively cyto-
plasmic staining in their cases and considered the same as
positive.
De Falco et al. have stated that in adult tissues, cyclin
D1 plays a role in proliferation and diﬀerentiation and the
shift between nucleus and cytoplasm is necessary to regulate
ﬁnely the passage across diﬀerent phases of the cell cycle. The
immunogoldobservationshaveindicatedtransitofcyclinD1
between nuclear and cytoplasmic compartments via nuclear
pores [17].
In the present study, cyclin D1 reactivity was seen in 45%
of cases. Some authorshave reported less than 45% reactivity
[4, 8, 9, 13–16, 21] while some have shown more [2, 3, 5,
10, 12, 16, 22–25]. These reported variations in reactivity
may be due to diverse reasons like asymmetric labelling ex-
pression seen in diﬀerent parts of same specimen owing to
the fact that in a specimen at a given time, only about 20%
of the neoplastic cells are under mitosis [8]. A discrepancy in
staining between the biopsy and surgical resection materials
has also been reported, most likely owing to tissue hetero-
geneity[26].Further,cyclinD1hasbeendescribedtoexpress
itself mainly in the peripheral layers of tumour islands and
not in the cells exhibiting mitosis [3]. The pRb gene also
appears to regulate transcription of the cyclin D1 which is
destabilizedinpRb-negativecellsandhencecellsnegativefor
pRb staining do not express cyclin D1; this may be due to the
fact that sometimes cyclin D1 acts as a negative regulator of
cell cycle progression [20]. Bartkova et al. reported that in
several common solid tumours, cyclin D1 protein may be
essential for G1 phase progression while some may have lost
thier requirement [27]. Further, an inverse relationship of
HPV status has also been reported with cyclin D1 expression
in OSCC [18].
To determine the cyclin D1 expression, we used a more
objective and inclusive method, as depicted by Gu et al. [7]
by multiplying the intensity score with labelling index score.
Whereas a few authors have used only a subjective evaluation
of intensity at three point criteria as “weak, moderate, and
strong” [2, 4, 28] or two point criteria as “weak and strong”
[21, 29] and considered it as ﬁnal expression. While some
other investigators have used labelling index score only as
ﬁnal expression [3, 5, 9, 10, 12, 14–16, 21, 23, 24, 30]. Maahs
et al. used stereologic method to determine labelling index
[8].
In our study, the labelling index did not have any cor-
relation withhistopathological diﬀerentiation and the results
could not be compared directly with other reported liter-
atures, because of diﬀerent criteria used for determining
scores by diﬀerent authors [3, 5, 9, 10, 12, 14–16, 21, 23, 24,
30].
The staining intensity was nonuniform, showing maxi-
mum cases of intermediate staining followed by weak and
strong. Angadi and Krishnapillai [2] and Mishra and Das
[4] noted a uniformly increasing intensity in relation to the
histopathological diﬀerentiation, whereas Castle et al. [28]
found no correlation.
In the present study, the cyclin D1 expression shown by
maximum number of cases was weak, followed by strong,
and intermediate. The expression had a signiﬁcant correla-
tion with histological diﬀerentiation. There was an increase
in cyclin D1 expression with increasing diﬀerentiation, that
is, highest expression was seen in WDSCC, followed by
MDSCC, and PDSCC. Since no studies on OSCC are avail-
ableintheliteratureusingthesimilarcriteriafordetermining
expression as used in the present study, we cannot directly
compare this data with that of others.
M a n ys t u d i e sh a v eb e e nd o n eo nc y c l i nD 1i nO S C C ,a n d
even though the controversy exists in the scientiﬁc literature,
it opens a window of opportunity for further discussion and
research in diﬀerent tumours with additional diﬀerent cri-
teria like lymph node involvement and metastasis. The inter-
pretation of the above study is precluded by its limited sam-
ple size and therefore the study should be followed further
with large sample size to validate our ﬁnding. The observa-
tions in this ﬁeld may contribute signiﬁcantly to the patient
well-being and decreased morbidity and mortality by estab-
lishing cyclin D1 as a better prognostic marker.
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